A Kunitz-type FXa inhibitor affects tumor progression, hypercoagulable state and triggers apoptosis

Biomedicine and Pharmacotherapy

Volumn 67, Issue 3, 2013, Pages 192-196

  Ventura, Janaína Souza ^a,b   Faria, Fernanda ^a   Batista, Isabel Fátima Correia ^a   Simons, Simone Michaela ^a,b   Oliveira, Daniella Gorete Lourenço ^a,b   Morais, Katia L P ^a,b   Chudzinski Tavassi, Ana Marisa ^a,b  

^a INSTITUTO BUTANTAN   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Amblyomin X; Antitumor; Apoptosis; Cell cycle; Coagulation; Heparin

Indexed keywords

AMBLOYOMIN X; ANTINEOPLASTIC AGENT; HEPARIN; RECOMBINANT PROTEIN; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HYPERCOAGULABILITY; IN VITRO STUDY; M PHASE CELL CYCLE CHECKPOINT; MALE; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; S PHASE CELL CYCLE CHECKPOINT;

ANIMALS; APOPTOSIS; CELL SURVIVAL; DISEASE PROGRESSION; FACTOR XA; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; SALIVARY PROTEINS AND PEPTIDES; THROMBOPHILIA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875508847     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2012.11.009     Document Type: Article

References (32)

1. Gerotziafas G.T., Papageorgiou C., Hatmi M., Samama M.M., Elalamy I. Clinical studies with anticoagulants to improve survival in cancer patients. Pathophysiol Haemost Thromb 2008, 36:204-211.
2. Wang J.G., Geddings J.E., Aleman M.M., Cardenas J.C., Chantrathammachart P., et al. Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood 2012, 119:5543-5552.
3. Bobek V. Anticoagulant and fibrinolytic drugs: possible agents in treatment of lung cancer?. Anticancer Agents Med Chem 2012, 12:580-588.
4. Hembrough T.A., Swartz G.M., Papathanassiu A., Vlasuk G.P., Rote W.E., et al. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism. Cancer Res 2003, 63:2997-3000.
5. Kakkar A.K., Levine M.N., Kadziola Z., Lemoine N.R., Low V., et al. Low-molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004, 22:1944-1948.
6. Mellor P., Harvey J.R., Murphy K.J., Pye D., O'Boyle G., et al. Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo. Br J Cancer 2007, 97:761-768.
7. Sousou T., Khorana A.A. New insights into cancer-associated thrombosis. Arterioscler Thromb Vasc Biol 2009, 29:316-320.
8. Bobek V., Kovarik J. Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother 2004, 58:213-219.
9. Li H.L., Ye K.H., Zhang H.W., Luo Y.R., Ren X.D., et al. Effect of heparin on apoptosis in human nasopharyngeal carcinoma CNE2 cells. Cell Res 2001, 11:311-315.
10. Meyer T., Hart I.R. Mechanisms of tumour metastasis. Eur J Cancer 1998, 34:214-221.
11. Zacharski L.R., Ornstein D.L. Heparin and cancer. Thromb Haemost 1998, 80:10-23.
12. Elias E.G., Shukla S.K., Mink I.B. Heparin and chemotherapy in the management of inoperable lung carcinoma. Cancer 1975, 36:129-136.
13. Zalpour A., Kroll M.H., Afshar-Kharghan V., Yusuf S.W., Escalante C. Role of factor Xa inhibitors in cancer-associated thrombosis: any new data?. Adv Hematol 2011, 2011:196135.
14. Batista I.F., Chudzinski-Tavassi A.M., Faria F., Simons S.M., Barros-Batestti D.M., et al. Expressed sequence tags (ESTs) from the salivary glands of the tick Amblyomma cajennense (Acari: Ixodidae). Toxicon 2008, 51:823-834.
15. Batista I.F., Ramos O.H., Ventura J.S., Junqueira-de-Azevedo I.L., Ho P.L., et al. A new Factor Xa inhibitor from Amblyomma cajennense with a unique domain composition. Arch Biochem Biophys 2010, 493:151-156.
16. Akagi E.M., Junior P.L., Simons S.M., Bellini M.H., Barreto S.A., et al. Pro-apoptotic effects of Amblyomin-X in murine renal cell carcinoma " in vitro" Biomed Pharmacother 2012, 66:64-69.
17. Chudzinski-Tavassi A.M., De-Sa-Junior P.L., Simons S.M., Maria D.A., de Souza Ventura J., et al. A new tick Kunitz-type inhibitor, Amblyomin-X, induces tumor cell death by modulating genes related to the cell cycle and targeting the ubiquitin-proteasome system. Toxicon 2010, 56:1145-1154.
18. Hoffmann J.J., Meulendijk P.N. Comparison of reagents for determining the activated partial thromboplastin time. Thromb Haemost 1978, 39:640-645.
19. Quick A.J. The prothrombin comsuption time test. J Clin Pathol 1966, 45(1):105-109.
20. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
21. Sakata Y., Iwamoto Y., Inata J., Matsumoto S., Miyamori S., et al. Adverse events during pemetrexed administration caused by concomitant nonsteroid anti-inflammatory therapy. Gan To Kagaku Ryoho 2012, 39:927-932.
22. Satyamoorthy K., Herlyn M. Cellular and molecular biology of human melanoma. Cancer Biol Ther 2002, 1:14-17.
23. Silbermann R., Roodman G.D. Bone effects of cancer therapies: pros and cons. Curr Opin Support Palliat Care 2011, 5:251-257.
24. Zacharski L.R., Prandoni P., Monreal M. Warfarin versus low-molecular-weight heparin therapy in cancer patients. Oncologist 2005, 10:72-79.
25. Kerk N., Strozyk E.A., Poppelmann B., Schneider S.W. The mechanism of melanoma-associated thrombin activity and von Willebrand factor release from endothelial cells. J Invest Dermatol 2010, 130:2259-2268.
26. Winters J., Garcia D. Cancer-associated thrombosis. Hematol Oncol Clin North Am 2010, 24:695-707. [viii].
27. Folkman J. Angiogenesis and angiogenesis inhibition: an overview. EXS 1997, 79:1-8.
28. Weis S.M., Cheresh D.A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011, 17:1359-1370.
29. Drewes C.C., Dias R.Y., Hebeda C.B., Simons S.M., Barreto S.A., et al. Actions of the Kunitz-type serine protease inhibitor Amblyomin-X on VEGF-A-induced angiogenesis. Toxicon 2012, 60:333-340.
30. Nawrocki S.T., Carew J.S., Dunner K., Boise L.H., Chiao P.J., et al. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER-stress in human pancreatic cancer cells. Cancer Res 2005, 65:11510-11519.
31. Shahshahan M.A., Beckley M.N., Jazirehi A.R. Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects. Am J Cancer Res 2011, 1:913-924.
32. Sciumbata T., Caretto P., Pirovano P., Pozzi P., Cremonesi P., et al. Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival. Invasion Metastasis 1996, 16:132-143.